|
C14ORF119 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
<1E-12 |
| Normal-vs-Stage2 |
1.21760000004745E-06 |
| Normal-vs-Stage3 |
1.62436730732907E-12 |
| Normal-vs-Stage4 |
1.01740005309381E-09 |
| Stage1-vs-Stage2 |
1.295750E-01 |
| Stage1-vs-Stage3 |
7.195600E-01 |
| Stage1-vs-Stage4 |
3.763700E-02 |
| Stage2-vs-Stage3 |
9.598200E-02 |
| Stage2-vs-Stage4 |
9.639800E-01 |
| Stage3-vs-Stage4 |
3.631600E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.96349999999068E-05 |
| Normal-vs-Asian |
2.26207941267376E-12 |
| Caucasian-vs-AfricanAmerican |
3.548200E-01 |
| Caucasian-vs-Asian |
4.629400E-01 |
| AfricanAmerican-vs-Asian |
1.697570E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.11732886568461E-14 |
| Normal-vs-Female |
1.62447832963153E-12 |
| Male-vs-Female |
6.000100E-02 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62436730732907E-12 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.0636999947522E-08 |
| Normal-vs-Age(81-100Yrs) |
3.70819999999661E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.403600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.966300E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.683400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.836170E-03 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.370400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.856000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.438850E-01 |
| Classical-VS-Follicular |
2.22544205286113E-12 |
| Classical-VS-Other |
2.517200E-01 |
| Classical-VS-Normal |
1.62436730732907E-12 |
| Tall-VS-Follicular |
8.09110001220859E-09 |
| Tall-VS-Other |
1.807610E-01 |
| Tall-VS-Normal |
1.65545355201857E-12 |
| Follicular-VS-Other |
2.786200E-01 |
| Follicular-VS-Normal |
2.304400E-03 |
| Other-VS-Normal |
8.477800E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.11022302462516E-16 |
| Normal-vs-N1 |
1.63159999955198E-07 |
| N0-vs-N1 |
2.652000E-01 |
|
|
